Immunotherapy in the treatment of advanced or recurrent endometrial cancer
Clin Adv Hematol Oncol. 2024 Apr;22(3):129-139.ABSTRACTThe standard treatment of patients with advanced or recurrent endometrial cancer has not significantly changed over the past few decades, reflecting a major unmet clinical need. Fortunately, the arrival of immune checkpoint inhibition is rapidly changing this dismal scenario. This review discusses the most recent results from clinical trials evaluating the use of immune checkpoint inhibitors, either as monotherapy or in combination therapy, in both the post-platinum and frontline settings. Additionally, a section is devoted to the future clinical development of immune checkpoint inhibitors in advanced or recurrent endometrial cancer.PMID:38588272
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Authors: Juan Francisco Grau-Bejar Lorena Farinas-Madrid Carmen Garc ía-Duran David Garc ía-Illescas Roberta Mazzeo Ana Oaknin Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Endometrial Cancer | Hematology | Immunotherapy